Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance

Biogen IncTrade
Global X Autonomous & Electric VehiclesTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Global X Autonomous & Electric Vehicles — how do they compare? Biogen Inc trades at $207.27 (market cap $30.13B), while Global X Autonomous & Electric Vehicles trades at $35.85. The key difference: Biogen Inc is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.

BIIBDRIV
Market Cap
$30.13B
Sector
HealthSector/Thematic
52-Week High
$216.63$42.53
52-Week Low
$128.93$25.23
Enterprise Value
$37.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

Global X Autonomous & Electric Vehicles

DRIV trades at $35.85, up 0.79% today, with a bullish technical signal from moving averages and oscillators. The stock shows strong momentum, though the 6-day RSI indicates overbought conditions. Recent news highlights global EV sales growth, with DRIV outperforming peers due to its focus on autonomous technology and software, gaining 38% year-to-date according to Seeking Alpha on 2026-05-14.

The outlook remains positive given sector tailwinds, but risks include competitive pressures from Chinese automakers and sensitivity to fuel price fluctuations. Analyst sentiment is bullish, supported by institutional interest in EV and autonomous driving exposure.

Returns comparison

Trailing returns across standard periods

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About Global X Autonomous & Electric Vehicles

DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.

Read more on DRIV